methyl 6-(4-ethylpiperazin-1-yl)nicotinate | 132144-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: methyl 6-(4-ethylpiperazin-1-yl)nicotinate
• 英文别名: Methyl 6-(4-ethyl-1-piperazinyl)-3-pyridinecarboxylate；methyl 6-(4-ethylpiperazin-1-yl)pyridine-3-carboxylate
• CAS: 132144-05-9
• 化学式: C₁₃H₁₉N₃O₂
• 分子量: 249.313
• InChiKey: PWLPXAALAIXFHZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(1-(2,6-dichlorobenzyl)-1H-benzo[d]imidazol-6-yl)-1H-pyrazol-3-amine 、 methyl 6-(4-ethylpiperazin-1-yl)nicotinate 在 trimethylaluminum 作用下， 以 甲苯 为溶剂， 反应 8.0h， 以6%的产率得到N-(5-(1-(2,6-dichlorobenzyl)-1H-benzo[d]imidazol-6-yl)-1H-pyrazol-3-yl)-6-(4-ethylpiperazin-1-yl)nicotinamide
  参考文献：
  名称：

  Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

  摘要：

  DOI：

  10.1021/acs.jmedchem.1c01196
• 作为产物：
  描述：

  N-乙基哌嗪 、 6-溴烟酸甲酯 在 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 甲苯 为溶剂， 反应 6.0h， 以51%的产率得到methyl 6-(4-ethylpiperazin-1-yl)nicotinate
  参考文献：
  名称：

  Discovery of a Potent FLT3 Inhibitor (LT-850-166) with the Capacity of Overcoming a Variety of FLT3 Mutations

  摘要：

  DOI：

  10.1021/acs.jmedchem.1c01196

文献信息

• Pyridinecarboxamide derivatives
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：US06046201A1

  公开（公告）日：2000-04-04

  N-(12-Nitroxydodecyl)-6-(4-ethyl or isopropyl-1-piperazinyl)pyridine-3-carboxamide or physiologically acceptable salts thereof. The said compounds have excellent inhibiting activity of cerebral edema, especially ischemic cerebral edema, and inhibiting activity of delayed neuronal death (an inhibiting activity of Ca-influx in neuronal cells). Cerebral edema is a pathologic condition accompanying cerebrovascular disorders, especially the acute stage cerebrovascular disorders and then the compounds are useful as an inhibiting agent for cerebral edema or a therapeutic agent for cerebrovascular disorders. Moreover, because the compounds do hardly show a behavior suppressing action, which is considered to be side effect in treating cerebrovascular disorders at the acute stage, they are an excellent therapeutic agent for, in particular, the acute stage cerebrovascular disorders. Moreover, the compounds show a cerebral protective activity (an anti-anoxic activity), an activity of increasing cerebral blood flow, and an activity of inhibiting lipid peroxidation, and these activities may lead to the increased utility as a therapeutic agent for cerebrovascular disorders.

  N-(12-硝基氧代十二烷基)-6-(4-乙基或异丙基-1-哌嗪基)吡啶-3-羧酰胺或其生理学上可接受的盐。该化合物具有出色的抑制脑水肿的活性，特别是缺血性脑水肿和延迟性神经元死亡的抑制活性（神经细胞中钙离子流入的抑制活性）。脑水肿是伴随脑血管疾病的病理状况，特别是急性期脑血管疾病，然后该化合物可用作脑水肿的抑制剂或脑血管疾病的治疗剂。此外，由于该化合物几乎不显示抑制行为，这被认为是治疗急性期脑血管疾病的副作用，因此它是一种优秀的治疗剂，特别是针对急性期脑血管疾病。此外，该化合物显示出脑保护活性（抗缺氧活性），增加脑血流的活性和抑制脂质过氧化的活性，这些活性可能导致其作为脑血管疾病治疗剂的增加实用性。
• Nicotinic acid derivatives and pharmaceutical compositions comprising same
  申请人：NISSHIN FLOUR MILLING CO., LTD.

  公开号：EP0385351A1

  公开（公告）日：1990-09-05

  Compounds are disclosed of the formula wherein R1 is hydrogen or C1-C6 alkyl; Y is -CH2-, -O-, R2 is C1-C6 alkyl; C2-C6 alkenyl; C3-C6 cycloalkyl; phenyl which may be mono- or di-substituted on the phenyl ring with C1-C6 alkoxy; aralkyl which may be mono- or di-substituted on the aromatic ring with C1-C6 alkoxy; diphenylmethyl; carboalkoxy; or an O- or N-heterocyclic radical which is linked to the nitrogen atom via carbonyl or carbonylmethylene; m is 2 or 3; and n is 0 or 1, and physiologically acceptable acid addition salts thereof. The compounds of formula (I) are of a blood flow-increasing action and can be used for the therapy or prevention of diseases in the cardiovascular system.

  所公开的化合物式如下 其中 R1 是氢或 C1-C6 烷基； Y 是-CH2-、-O-、 R2是C1-C6烷基；C2-C6烯基；C3-C6环烷基；苯基，可在苯基环上用C1-C6烷氧基单取代或二取代；芳香环上用C1-C6烷氧基单取代或二取代的芳基；二苯基甲基；羧基烷氧基；或通过羰基或羰基亚甲基与氮原子相连的O-或N-杂环基； m为2或3 和 n 是 0 或 1，以及它们的生理上可接受的酸加成盐。式（I）化合物 具有增加血流量的作用，可用于治疗或预防心血管系统疾病。
• PYRIDINECARBOXAMIDE DERIVATIVES
  申请人：Nisshin Flour Milling Co., Ltd.

  公开号：EP0882716A1

  公开（公告）日：1998-12-09

  N-(12-Nitroxydodecyl)-6-(4-ethyl or isopropyl-1-piperazinyl)pyridine-3-carboxamide or physiologically acceptable salts thereof. The said compounds have excellent inhibiting activity of cerebral edema, especially ischemic cerebral edema, and inhibiting activity of delayed neuronal death (an inhibiting activity of Ca-influx in neuronal cells). Cerebral edema is a pathologic condition accompanying cerebrovascular disorders, especially the acute stage cerebrovascular disorders and then the compounds are useful as an inhibiting agent for cerebral edema or a therapeutic agent for cerebrovascular disorders. Moreover, because the compounds do hardly show a behavior suppressing action, which is considered to be side effect in treating cerebrovascular disorders at the acute stage, they are an excellent therapeutic agent for, in particular, the acute stage cerebrovascular disorders. Moreover, the compounds show a cerebral protective activity (an anti-anoxic activity), an activity of increasing cerebral blood flow, and an activity of inhibiting lipid peroxidation, and these activities may lead to the increased utility as a therapeutic agent for cerebrovascular disorders.

  N-(12-硝基十二烷基)-6-(4-乙基或异丙基-1-哌嗪基)吡啶-3-甲酰胺或其生理上可接受的盐类。 上述化合物对脑水肿（尤其是缺血性脑水肿）有很好的抑制作用，对延迟神经元死亡（抑制神经元细胞中 Ca 的流入）也有很好的抑制作用。脑水肿是脑血管疾病，尤其是急性期脑血管疾病的一种病理状态，因此，这些化合物可作为脑水肿的抑制剂或脑血管疾病的治疗剂。此外，由于这些化合物在急性期治疗脑血管疾病时几乎不表现出被认为具有副作用的行为抑制作用，因此，它们尤其是急性期脑血管疾病的极佳治疗剂。此外，这些化合物还具有脑保护活性（抗缺氧活性）、增加脑血流量的活性和抑制脂质过氧化的活性，这些活性可能会增加其作为脑血管疾病治疗剂的效用。
• Pyridinecarboxylic acid amide derivatives and pharmaceutical compositions comprising same
  申请人：NISSHIN FLOUR MILLING CO., LTD.

  公开号：EP0385350B1

  公开（公告）日：1994-11-30
• US4994456A
  申请人：——

  公开号：US4994456A

  公开（公告）日：1991-02-19